Results 21 to 30 of about 10,491 (187)

Raltegravir Inclusion Decreases CD4 T-Cells Intra-Cellular Viral Load and Increases CD4 and CD28 Positive T-Cells in Selected HIV Patients

Cells, 2022
Raltegravir (RLT) prevents the integration of HIV DNA in the nucleus, but published studies remain controversial, suggesting that it does not decrease proviral DNA. However, there are only a few studies focused on virus-targeted cells. We aimed our study
Gaurav Kumar, Jacqueline Cottalorda-Dufayard, Rodolphe Garraffo, Francine De Salvador-Guillouët, Eric Cua, Pierre-Marie Roger   +5 more
doaj   +1 more source

Maternal–Neonatal Raltegravir Population Pharmacokinetics Modeling: Implications for Initial Neonatal Dosing

CPT: Pharmacometrics & Systems Pharmacology, 2019
Raltegravir readily crosses the placenta to the fetus with maternal use during pregnancy. After birth, neonatal raltegravir elimination is highly variable and often extremely prolonged, with some neonates demonstrating rising profiles after birth despite
Jos Lommerse, Diana Clarke, Thomas Kerbusch, Henri Merdjan, Han Witjes, Hedy Teppler, Mark Mirochnick, Edward P. Acosta, Larissa Wenning, Sharon Nachman, Anne Chain   +10 more
doaj   +1 more source

Adverse events of raltegravir and dolutegravir [PDF]

, 2017
OBJECTIVE To compare the frequency and risk factors of toxicity-related treatment discontinuations between raltegravir and dolutegravir. DESIGN Prospective cohort study.
Swiss HIV Cohort Study, Battegay, Manuel, Erb, Stefan, Enos Bernasconi, Furrer, Hansjakob, Hansjakob Furrer, Alexandra Calmy, Stefan Erb, Luigia Elzi, Manuel Battegay, Elzi, Luigia, Huldrych Günthard, Pietro Vernazza, Vernazza, Pietro, Günthard, Huldrych, Calmy, Alexandra, Cavassini, Matthias, Bernasconi, Enos, Matthias Cavassini   +18 more
core   +1 more source

Selective and rapid determination of raltegravir in human plasma by liquid chromatography–tandem mass spectrometry in the negative ionization mode

Journal of Pharmaceutical Analysis, 2015
A selective and rapid high-performance liquid chromatography–tandem mass spectrometry method was developed and validated for the quantification of raltegravir using raltegravir-d3 as an internal standard (IS).
Ajay Gupta, Swati Guttikar, Priyanka A. Shah, Gajendra Solanki, Pranav S. Shrivastav, Mallika Sanyal   +5 more
doaj   +1 more source

Effectiveness and safety of integrase strand transfer inhibitors in Spain: a prospective real-world study

Frontiers in Cellular and Infection Microbiology, 2023
IntroductionSecond-generation integrase strand transfer inhibitors (INSTIs) are preferred treatment options worldwide, and dolutegravir (DTG) is the treatment of choice in resource-limited settings.
José Ramón Santos, Maria Casadellà, Marc Noguera-Julian, Rafael Micán-Rivera, Pere Domingo, Antonio Antela, Joaquin Portilla, Jesús Sanz, Marta Montero-Alonso, Jordi Navarro, Mar Masiá, Mar Masiá, Nieves Valcarce-Pardeiro, Antonio Ocampo, Laura Pérez-Martínez, Coral García-Vallecillos, María Jesús Vivancos, María Jesús Vivancos, Arkaitz Imaz, José Antonio Iribarren, José Hernández-Quero, Judit Villar-García, Pilar Barrufet, Roger Paredes, Roger Paredes, INSTINCT study group, Mariona Perera, Anna Chamorro, Cristina Miranda, Nástor Sánchez, Anna Garcı́á, Núria Pérez, Juan González Garcı́á, María del Mar Gutiérrez, María Gracia Mateo, Elena Losada, Sergio Reus, Vicente Boix, Diego Torrús, Esperanza Merino, Angela Gutiérrez Liarte, Adrià Curran, Félix Gutiérrez, Anna Mariño Callejo, Alvarez Diaz Hortensia, Antonio Ocampo Hermida, Celia Miralles, Laura Labajo Leal, Guillermo Pousada, José Ramon Blanco, José Antonio Oteo, Ibarra Valvanera, Mercedes Sanz, Luis Metola, Juan Pascua, Daniel Podzamczer, Camila Piatti, Maialen Ibarguren, Laia Arbones, Marta Ruiz, Sara Cervanntes, Helena Pera, Jessica Toro, Nuria Perez-Alvarez, Anna Garcia   +64 more
doaj   +1 more source

Phenotyping of UGT1A1 Activity Using Raltegravir Predicts Pharmacokinetics and Toxicity of Irinotecan in FOLFIRI.

PLoS ONE, 2016
BackgroundIrinotecan toxicity correlates with UGT1A1 activity. We explored whether phenotyping UGT1A1 using a probe approach works better than current genotyping methods.MethodsTwenty-four Asian cancer patients received irinotecan as part of the FOLFIRI ...
Lawrence Soon-U Lee, Kok-Yong Seng, Ling-Zhi Wang, Wei-Peng Yong, Kim-Hor Hee, Thomas I Soh, Andrea Wong, Pei F Cheong, Richie Soong, Nur S Sapari, Ross Soo, Lu Fan, Soo-Chin Lee, Boon C Goh   +13 more
doaj   +1 more source

Evaluation of Circulating and Archived HIV-1 Integrase Drug-Resistance Variants among Patients on Third-Line ART in Cameroon: Implications for Dolutegravir-Containing Regimens in Resource-Limited Settings

Microbiology Spectrum, 2022
To ensure the long-term efficacy of dolutegravir (DTG), we evaluated the genotypic profile in viral reservoirs among patients on third-line (3L) antiretroviral therapy (ART) in Cameroon, according to prior exposure to raltegravir (RAL).
Joseph Fokam, Ezechiel Ngoufack Jagni Semengue, Evariste Molimbou, Naomi-Karell Etame, Maria Mercedes Santoro, Désiré Takou, Leonella Mossiang, Alain Patrice Meledie, Collins Ambe Chenwi, Bouba Yagai, Alex Durand Nka, Beatrice Dambaya, Georges Teto, Aude Christelle Ka’e, Grâce Angong Beloumou, Sandrine Claire Djupsa Ndjeyep, Nadine Fainguem, Aissatou Abba, Aurelie Minelle Ngueko Kengni, Michel Carlos Tommo Tchouaket, Nounouce Pamen Bouba, Serge-Clotaire Billong, Rina Djubgang, Edith Temgoua Saounde, Samuel Martin Sosso, Charles Kouanfack, Anne-Cecile Zoung-Kanyi Bissek, Emmanuel Eben-Moussi, Vittorio Colizzi, Carlo-Federico Perno, Francesca Ceccherini-Silberstein, Alexis Ndjolo   +31 more
doaj   +1 more source

Features of application of raltegravir in HIV-infected patients with different somatic pathologies

Журнал инфектологии, 2021
Purpose of the study. Evaluation of the efficacy, safety and tolerability of raltegravir regimens in HIV-infected patients with concomitant pathology in real clinical practice.Materials and methods.
N. V. Sizova, E. S. Obizhaeva, S. O. Mayorova   +2 more
doaj   +1 more source

Perinatal and early infant outcomes after first-versus second-generation integrase strand transfer inhibitor use in pregnancy. [PDF]

HIV Med
Abstract Introduction Integrase strand transfer inhibitors (INSTIs) are first‐line antiretroviral medications used in pregnancy. Pre‐clinical research suggests adverse effects in human stem cells associated with second‐ versus first‐generation INSTIs.
Balleny R, Wong JMH, Lee T, Bitnun A, Boucoiran I, Brophy J, Comeau J, Kakkar F, McConnell A, Sauvé L, Singer J, Tse-Chang A, Money D.   +12 more
europepmc   +2 more sources

Divalent metals and pH alter raltegravir disposition in vitro [PDF]

, 2012
Raltegravir shows marked pharmacokinetic variability in patients, with gastrointestinal pH and divalent-metal binding being potential factors. We investigated raltegravir solubility, lipophilicity, pKa, and permeativity in vitro to elucidate known ...

core   +1 more source